Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
246.36 AUD | -1.77% | -2.62% | -14.39% |
Sep. 27 | Australian shares decline ahead of key inflation data | RE |
Sep. 18 | CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources | CI |
Sales 2024 * | 14,782 M 23,113 M | Sales 2025 * | 16,100 M 25,174 M | Capitalization | 78 178 M 122 B |
---|---|---|---|---|---|
Net income 2024 * | 2,748 M 4,297 M | Net income 2025 * | 3,336 M 5,216 M | EV / Sales 2024 * | 5,93x |
Net Debt 2024 * | 9,459 M 14,790 M | Net Debt 2025 * | 7,780 M 12,164 M | EV / Sales 2025 * | 5,34x |
P/E ratio 2024 * | 28,6x | P/E ratio 2025 * | 23,5x | Employees | - |
Yield 2024 * | 1,64% | Yield 2025 * | 1,86% | Free-Float | 99.95% |
More Fundamentals
* Assessed data
More news
More press releases
More news
1 day | -1.77% | ||
1 week | -2.62% | ||
Current month | -1.77% | ||
1 month | -8.22% | ||
3 months | -10.82% | ||
6 months | -15.31% | ||
Current year | -14.39% |
1 week
246.36
255.69

1 month
246.36
271.65

Current year
246.36
314.28

1 year
246.36
314.28

3 years
240.10
320.42

5 years
173.00
342.75

10 years
63.77
342.75

Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.91% | 30 M$ | +5.35% | - | |
2.49% | 4 M$ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-10-02 | 246.36 | -1.77% | 546 082 |
23-09-29 | 250.80 | -0.49% | 925,453 |
23-09-28 | 252.04 | 0.00% | 574,414 |
23-09-27 | 252.04 | -1.39% | 1,260,486 |
23-09-26 | 255.60 | +1.03% | 865,415 |
Delayed Quote Australian Stock Exchange, October 02, 2023 at 01:10 am EDT
More quotes
CSL Limited (CSL) is an Australia-based biotechnology company. The Company's areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company's segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company's CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company's geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL's products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.
Sector
Pharmaceuticals
Calendar
2023-10-10
- Annual General Meeting
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy

Mean consensus
BUY
Number of Analysts
16
Last Close Price
161.84USD
Average target price
210.18USD
Spread / Average Target
+29.87%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-14.39% | 78 178 M $ | |
-50.14% | 160 M $ | |
+78.04% | 2 618 M $ | |
-58.44% | 267 M $ | |
-.--% | 90 M $ | |
+80.97% | 958 M $ | |
-.--% | 1 365 M $ | |
-10.44% | 235 M $ | |
-23.73% | 24 780 M $ | |
-46.81% | 59 M $ |